Home » AGEB Journal » Issues » Volume 76" » Fasc.4 - Letters » Article details

Is really megacolon a contraindication to infliximab in Crohn's disease ?

Journal Volume 76 - 2013
Issue Fasc.4 - Letters
Author(s) Emanuele Sinagra, Ambrogio Orlando, Sara Renna, Valeria Criscuoli, Francesco La Seta, Mirko Olivo, Marco Ciofalo, Mario Cottone
Full article
Full Article
VIEW FREE PDF
(1) DIBIMIS, Ospedali Riuniti Villa Sofia - Vincenzo CervellO. Division of Internal Medicine, and (2) Radiology Unit, Palermo ; (3) DIBIMEF, Sezione di Scienze Radiologiche, AOUP Paolo Giaccone, Palermo ; (4) Fondazione Istituto San Raffaele GigliO. Gastroenterology & Endoscopi Unit, Cefalù, Italy.

Toxic megacolon (TM) is a rare complication of severe ulcerative colitis (UC) and colonic Crohn's disease (CD), defined as a clinical syndrome accompanied by radiographic evidence of colonic dilata- tion that in many cases must be treated aggressively with surgical intervention (1). We report two cases of steroid and antibiotic-refractory fulmi- nant Crohn's colitis, complicated by toxic megacolon, who were successfully treated with infliximab (IFX), thus avoiding surgical intervention. Although there are no well defined recommendation about the correct timing of colectomy in CD-associated TM, and despite the fact that it may be imprudent to advocate delaying surgery in favour of anti-tumor necrosis (anti-TNF) factor therapy in these cases, we think that a medical "rescue therapy" can be considered in a subset of patients with stable clinical condition during cortico- steroid treatment. (Acta gastroenterol. belg., 2013, 76, 442-444).

© Acta Gastro-Enterologica Belgica.
PMID 24592552